![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1553561
¹Ì±¹ÀÇ ¾Ð¹Ú ¿ä¹ý ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® ¸®Æ÷Æ® : ±â¼úº°, À¯Åë ä³Îº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2024-2030³â)U.S. Compression Therapy Market Size, Share & Trends Analysis Report By Technology (Static Compression Therapy, Dynamic Compression Therapy), By Distribution Channel, By End Use, By Region And Segment Forecasts, 2024 - 2030 |
Grand View Research, Inc.ÀÇ ÃֽЏ®Æ÷Æ®¿¡ µû¸£¸é ¹Ì±¹ÀÇ ¾Ð¹Ú ¿ä¹ý ½ÃÀåÀº 2030³â±îÁö 18¾ï 7,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ¿¹Ãø ±â°£ Áß CAGRÀº 2.90%ÀÔ´Ï´Ù.
¸¸¼ºÁ¤¸ÆºÎÀü(CVI)°ú ½ÉºÎÁ¤¸ÆÇ÷ÀüÁõ(DVT)°ú °°Àº ¸¸¼º Á¤¸Æ Áúȯ Áõ°¡À²Àº ¾Ð¹Ú ¿ä¹ý¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¾Ð¹Ú ¿ä¹ýÀº Ç÷¾× ¼øÈ¯À» °³¼±ÇÏ°í ºÎÁ¾À» °¨¼Ò½ÃÅ´À¸·Î½á ÀÌ·¯ÇÑ Áõ»óÀ» °ü¸®ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù.
¹Ì±¹ ±¹¸³»ý¸í°øÇÐÁ¤º¸¼¾ÅÍ(National Center for Biotechnology Information 2022)¿¡ µû¸£¸é DVT´Â ¹Ì±¹¿¡¼ 20¸¸ ¸í ÀÌ»óÀÌ ¾Î°í ÀÖ´Â ÁúȯÀÔ´Ï´Ù. ±³À° Ä·ÆäÀΰú °Ç° ÁõÁø ±¸»óÀ» ÅëÇØ ¾Ð¹Ú ¿ä¹ýÀÇ ÀÌÁ¡¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼ ¼ÒºñÀÚ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¾Ð¹Ú ¿ä¹ýÀÌ ¾î¶»°Ô Áõ»óÀ» ¿ÏÈÇÏ°í »îÀÇ ÁúÀ» Çâ»ó½Ãų ¼ö ÀÖ´ÂÁö¿¡ ´ëÇÑ ÀÌÇØ´Â ¾Ð¹Ú ¿ä¹ýÀÇ µµÀÔÀ» ÃËÁøÇÕ´Ï´Ù. ¿¹¹æ ÀÇ·á¿Í Àڱ⠰ü¸®¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼ ¸¸¼ºÁúȯÀ» ¿¹¹æÇÏ°í °ü¸®Çϱâ À§ÇÑ »çÀü ¿¹¹æÃ¥À¸·Î ¾Ð¹Ú ¿ä¹ýÀ» »ç¿ëÇÏ´Â °ÍÀÌ ±ÇÀåµÇ°í ÀÖ½À´Ï´Ù.
ÀçÅÃÄ¡·á ¹× ¿Ü·¡ ȯÀÚ Ä¡·á·ÎÀÇ ÀüȯÀº ÀÓ»ó ÇöÀå ¹Û¿¡¼ »ç¿ëÇÒ ¼ö ÀÖ´Â ¾Ð¹Ú Ä¡·á Á¦Ç°¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼¿¡´Â Áö¼ÓÀûÀÎ »óÅ °ü¸®¸¦ À§ÇØ Áý¿¡¼ ¾Ð¹Úº¹°ú ¾Ð¹Ú±â±¸¸¦ »ç¿ëÇÏ´Â °Íµµ Æ÷ÇԵ˴ϴÙ. ÀçÅÃÄ¡·á ¼ºñ½º¿Í ¿Â¶óÀÎ ±¸¸Å ¿É¼ÇÀ¸·Î ÀÎÇØ ¾Ð¹Ú ¿ä¹ý Á¦Ç°ÀÌ È¯Àڵ鿡°Ô ´õ¿í Ä£¼÷ÇØÁö°í ÀÖ½À´Ï´Ù. ¾Ð¹Ú ¿ä¹ý Á¦Ç°¿¡ ´ëÇÑ °³¼±µÈ »óȯ Á¤Ã¥ ¹× º¸Çè Àû¿ëÀº ȯÀÚ¿Í ÀÇ·á ¼ºñ½º ÇÁ·Î¹ÙÀÌ´õÀÇ ÀçÁ¤Àû À庮À» ³·Ãç Á¦Ç° µµÀÔÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.
ÆÒµ¥¹ÍÀº ¾Ð¹Ú Ä¡·á Á¦Ç°À» Æ÷ÇÔÇÑ ÀÇ·á ¿ëǰÀÇ Á߿伺¿¡ ´ëÇÑ ÀνÄÀ» ³ôÀÌ´Â °è±â°¡ µÇ¾úÀ¸¸ç, COVID-19 ÁßÁõ ȯÀÚ, ƯÈ÷ ÀÔ¿ø ±â°£ÀÌ ±æ¾îÁö°Å³ª ½ÉºÎÁ¤¸ÆÇ÷ÀüÁõ(DVT)°ú °°Àº ÇÕº´ÁõÀ» °æÇèÇÑ È¯ÀÚµéÀº ¾Ð¹Ú Ä¡·á Á¦Ç°¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½ÃÄ×½À´Ï´Ù. ÆÒµ¥¹ÍÀº Àü ¼¼°è °ø±Þ¸Á¿¡ Å« È¥¶õÀ» ÀÏÀ¸ÄÑ ¾Ð¹Ú ¿ä¹ý Á¦Ç°ÀÇ »ý»ê°ú À¯Åë¿¡ ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù. °øÀå °¡µ¿ Áß´Ü, °øÀå Æó¼â ¹× ¹è¼Û Áö¿¬À¸·Î ÀÎÇØ ¿øÀÚÀç ¹× ¿ÏÁ¦Ç° ¼ö±Þ¿¡ ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù. COVID-19 °ü·Ã ÇÕº´Áõ ¹× ±âŸ °Ç° »óŸ¦ À§ÇÑ »õ·Î¿î ¾Ð¹Ú ¿ä¹ý ¼Ö·ç¼Ç °³¹ß µî ÇコÄÉ¾î ºÐ¾ßÀÇ ¿¬±¸ ¹× °³¹ß ³ë·ÂÀ» °¡¼ÓÈÇß½À´Ï´Ù.
¾Ð¹Ú ¿ä¹ý ½ÃÀåÀº ¹Ì±¹ ½ÄǰÀǾ౹(FDA)°ú °°Àº ±â°üÀÇ ¾ö°ÝÇÑ ±ÔÁ¦ ¿ä°ÇÀ» ÁؼöÇØ¾ß ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ±ÔÁ¦¸¦ ÁؼöÇÏ´Â °ÍÀº Á¦Á¶¾÷ü¿¡°Ô µµÀüÀÌ µÉ ¼ö ÀÖ°í ºñ¿ëÀÌ ¸¹ÀÌ µì´Ï´Ù. ½º¸¶Æ® ±â¼úÀ̳ª ¸ÂÃãÇü ÇÇÆÃ°ú °°Àº ÷´Ü ¾Ð¹Ú ¿ä¹ý Á¦Ç°Àº °í°¡ÀÏ ¼ö ÀÖ½À´Ï´Ù. ³ôÀº ºñ¿ëÀ¸·Î ÀÎÇØ ÀϺΠȯÀÚ³ª ÀÇ·á ½Ã¼³¿¡¼´Â Á¢±ÙÇϱ⠾î·Á¿ï ¼ö ÀÖ½À´Ï´Ù. ¾Ð¹Ú ¿ä¹ý Á¦Ç°¿¡ ´ëÇÑ º¸Çè Àû¿ë ¹× »óȯ Á¤Ã¥Àº Àϰü¼ºÀÌ ¾øÀ¸¸ç, º¸Çè»ç¸¶´Ù Å©°Ô ´Ù¸¦ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Â÷À̴ ȯÀÚ¿¡°Ô °æÁ¦Àû ºÎ´ãÀ» ÁÖ°í ½ÃÀå ¼ºÀå¿¡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ½À´Ï´Ù. ½ÃÁß¿¡¼ ÆÇ¸ÅµÇ´Â ¾Ð¹Ú ¿ä¹ý Á¦Ç°ÀÇ Ç°Áú°ú È¿°ú´Â ´Ù¾çÇÕ´Ï´Ù. Á¦Á¶¾÷üµéÀº ¸ðµç Á¦Ç°ÀÌ ¼º´É°ú ¾ÈÀü¿¡ ´ëÇÑ ³ôÀº ±âÁØÀ» ÃæÁ·ÇØ¾ß ÇÏ´Â °úÁ¦¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù.
The U.S. compression therapy market is anticipated to reach USD 1.87 billion by 2030, exhibiting a CAGR of 2.90% during the forecast period, according to a new report by Grand View Research, Inc. Rising rates of chronic venous disorders, such as chronic venous insufficiency (CVI) and deep vein thrombosis (DVT), drive demand for compression therapy. Compression therapy helps manage these conditions by improving blood circulation and reducing swelling.
According to the National Center for Biotechnology Information 2022, DVT affects more than 200,000 people in the U.S. Increased awareness about the benefits of compression therapy through educational campaigns and health promotion initiatives drives consumer demand. Understanding how compression therapy can alleviate symptoms and improve quality of life encourages adoption. The growing emphasis on preventive health and self-care encourages the use of compression therapy as a proactive measure to prevent or manage chronic conditions.
The shift towards home healthcare and outpatient care increases the demand for compression therapy products that can be used outside of clinical settings. This trend includes the use of compression garments and devices at home for ongoing condition management. Home healthcare services and online purchasing options make compression therapy products more accessible to patients. Improved reimbursement policies and insurance coverage for compression therapy products help reduce financial barriers for patients and healthcare providers, which facilitates the adoption of these products.
The pandemic led to increased awareness of the importance of medical supplies, including compression therapy products. Patients recovering from severe cases of COVID-19, especially those with extended hospital stays or who experienced complications such as deep vein thrombosis (DVT), have heightened demand for compression therapy. The pandemic caused significant disruptions in global supply chains, affecting the production and distribution of compression therapy products. Lockdowns, factory closures, and shipping delays impacted the availability of raw materials and finished goods. The pandemic accelerated research and development efforts in the healthcare sector, including the development of new compression therapy solutions that address both COVID-19-related complications and other health conditions.
The compression therapy market is subject to stringent regulatory requirements set by organizations such as the Food and Drug Administration. Ensuring compliance with these regulations can be challenging and costly for manufacturers. Advanced compression therapy products, such as those with smart technology or custom fittings, can be expensive. High costs may limit accessibility for some patients and healthcare facilities. Insurance coverage and reimbursement policies for compression therapy products can be inconsistent and vary widely among insurers. This variability can create financial burdens for patients and affect market growth. The quality and effectiveness of compression therapy products available in the market vary. Manufacturers face a challenge in ensuring that all products meet high standards for performance and safety.